
Senior Science Correspondent for @Endpts covering biotech, drug discovery, gene editing, RNA, and more. Formerly at Boston Globe and C&EN. Signal: RyanCross.25
Joined February 2015
- Tweets2.4K
- Following848
- Followers4.6K
- Likes2.3K
The Science Boss is back! It's my first day at @endpts, a @FinancialTimes co. I'll be writing news, analysis, and features as the Senior Science Correspondent for Endpoints, with a focus on the science, reseach, and tech of biomed, biotech, and pharma.
[email protected]
Lilly’s dopamine drug mevidalen fails Phase 2 study in Alzheimer’s, according to data at #CTAD26. The company hasn't said much about the pill, but it was one of its efforts to branch out beyond amyloid antibodies. My story for @endpts has the details: endpoints.news/ctad26-lillys…
2
434
Biogen’s tau-silencing drug diranersen slows Alzheimer’s by 38% after nearly two years, up from 26% slowing after 18 months, according to data at #CTAD26. But lots of caveats, including a small group and imperfect placebo comparison. Details in @endpts - endpoints.news/ctad26-biogen…
6
596
Cognito plans FDA submission of light and sound therapy for Alzheimer’s despite missing its primary endpoint in both the overall population and mild disease subgroup. Data of pivotal study presented at #CTAD26. My story for @endpts has the details: endpoints.news/ctad26-cognit…
1
366
For nearly a decade, the German biotech Priavoid has been working on a pill to break up small clumps of amyloid proteins. In a 300-person study presented at #CTAD26 this morning, the drug failed to slow Alzheimer's disease. More details in @endpts: endpoints.news/priavoids-amy…
229
A shocking twist in the sickle cell saga. Nearly 3 years after the FDA approved two one-and-done gene therapies for the disease, a new startup has raised $173M for siRNA drug, dosed chronically, that targets the same gene as the CRISPR therapy. @endpts: endpoints.news/marrow-raises…
AriBio’s repurposed erectile dysfunction drug for Alzheimer’s disease yields tepid results: no significant difference from placebo in overall study, but 31% slowing of cognitive decline in people who weren't on two other common Alzheimer's drugs. @endpts endpoints.news/aribios-repur…
2
3
698
"If we’re not, in the US, providing an outlet for our scientific discovery to move toward patient benefit, others will step into that void, and that’s what we’re seeing."
More on cancer's translation problem in my Q&A with Parker Institute's Karen Knudsen endpoints.news/parker-instit…
1
224
Seawolf launches with $100M to make non-viral gene therapies for obesity, muscle loss and osteoporosis. The startup told me the key to delivering DNA with LNPs was a protein that blocks the cell's natural sequestration of foreign DNA. More in @endpts endpoints.news/seawolf-launc…
Endpoints News is hiring a "Business of Science" reporter! We're looking for someone with experience covering the biotech industry with business savvy and an ability to make sense of important advances in science and medicine. @endpts linkedin.com/jobs/view/44899…
Cancer immunotherapy has struggled to build on its initial success. Big pharma is backing out of the field, and former Genentech leader Ira Mellman is forming a plan to keep the promise of immunotherapy alive at the Parker Institute. My latest for @endpts: endpoints.news/ira-mellman-w…
London startup Oyster Therapeutics raises $60M for self-assembling protein degraders, dubbed SELFTACs, aimed at the Alzheimer’s protein tau. More details on the approach in my story for @endpts: endpoints.news/london-startu…
Backed by Amish and Mennonites, a new kind of gene therapy company takes shape.
@leilei_wuu has the incredible story for @endpts about a community carrying a rare disease that drugmakers won't invest in, so they are developing a treatment themselves. endpoints.news/backed-by-ami…
Ferring Pharma, one of the biggest sellers of fertility drugs used in IVF, plans to acquire the ovary-in-a-dish startup Gameto for up to $1.38B.
Gameto has made iPSC-derived ovarian support cells that help mature human eggs in the lab. Read more @endpts: endpoints.news/ferring-to-ac…
Alnylam @Alnylam $ALNY plans bigger study of its siRNA drug for Huntington’s disease after new Phase 1 data suggests some of the best reduction of the disease-linked mHTT protein yet. But its a tough field. More details in my story for @endpts: endpoints.news/alnylam-plans…
7
510
China biotech RiboX reveals first data of a circular RNA therapy in people, with benefits seemingly lasting six months. “That seems pretty crazy, but it’s possible, I guess,” an RNA biologist in Boston told me. My story for @endpts has the details: endpoints.news/china-biotech…
Astellas partners with Boston ‘miniproteins’ startup AI Proteins. Details in my exclusive for @endpts: - endpoints.news/exclusive-ast…
We've got a great event at @endpts starting up at 11:00 am ET.
I'm interviewing Stanford's @lecong, Basecamp's John Finn and Waterfall Scientific's Melissa Moore (former Moderna CSO) about the intersection of AI and genetic medicine.
Tune in here: events.endpoints.news/aiday2…
2
231
Arrowhead’s brain-targeting siRNA, administered as a subcutaneous injection, lowers the Alzheimer’s protein tau in early study. Lots of work ahead here, but good news for delivery tech designed to cross the blood-brain barrier. My story for @endpts: - endpoints.news/arrowheads-br…
286
For decades, Rudolph Tanzi has dreamt of a “little white pill” to prevent Alzheimer’s disease. Now, his startup Acta Pharma is getting ready to test a drug that could block the buildup of amyloid plaques. My deep dive for @endpts has the details: endpoints.news/rudy-tanzi-ha…
1
347
Bexorg got a $28M ARPA-H award to run longer tests on ‘rebooted’ human brains (don't call them "alive") obtained from organ donaors. Last year, they were limiting most tests to 24 hours. Now they will try to keep the brains running for two weeks. @endpts endpoints.news/bexorg-gets-2…
2
1
188
Bexorg is using its brain-rebooting technology to study drugs before they are tested in living humans. My deep dive I wrote for Endpoints last year gets into the scientific, ethical and businsess details: endpoints.news/rebooting-dea…
1
1
131

